NRG ONCOLOGY

It's FORTE Fridays! Check out the April issue here ➡️https://conta.cc/4bVexa7

Tune in to the NRG Oncology Podcast after the SGO Session Plenary to hear us dive into the reported results of NRG-GY019 in #ovariancancer - Still not following us? Listen & find where to follow at https://lnkd.in/eEM34-yv

April is #HeadAndNeckCancerAwarenessMonth. This includes cancers in the larynx, throat, lips, mouth, nose, and salivary glands. Learn more about symptoms, prevention, & screening resources on the NCI’s website: https://ow.ly/AiqN50VrKPw

Protocol Activation! NRG-CC017: A randomized phase III study comparing temporally-modulated pulsed radiation therapy (TMPRT) versus standard radiation therapy with temozolomide for adults with newly diagnosed MGMT-unmethylated glioblastoma https://conta.cc/3PKI3bl

March is #colorectalcancerawarenessmonth. Don't forget ➡️ 45 is the new 50 & if you have symptoms ↪️ any age is the right age to #GetScreened. A colonoscopy can find polyps early! Talk to your doctor about screenings.

NRG Oncology Weekly Broadcast for March 30, 2026: https://conta.cc/3PwxpVF

PRESS RELEASE: NRG Oncology Adds New Leadership Members to Ancillary Projects, Investigator & Career Development, Medical Oncology, Patient-Centered Outcomes Research, and Surgical Oncology Committees & Sarcoma Subcommittee. Read the release: https://ow.ly/q2CI50YAH7f

Today is #NationalDoctorsDay! Thank you to all of the doctors & researchers who help us design & conduct #clinicaltrials to improve the standard of care for patients with cancer. #Gratitude #DoctorsDay

For #KidneyCancerAwarenessMonth, throwing out this reminder about NRG Oncology Podcast featuring an interview with NRG-GU012 “SAMURAI” study team - Drs. William Hall & Rana McKay, on this currently enrolling, Phase II study evaluating stereotactic ablative radiation therapy for patients with metastatic unresected renal cell carcinoma who are receiving immunotherapy. https://lnkd.in/eEM34-yv.

NRG-GU011 “A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN),” closed to accrual at 5 PM ET March 25, 2026, because it has reached its accrual target. Reminder: Data collection and site IRB renewal for closed studies must continue until the study is terminated.